Source: JD Supra

Multiple class action cases have been filed against Tempus AI alleging improper collection and disclosure of genetic information during its acquisition of Ambry Genetics. Tempus is said to have acquired Ambry, a genetic testing firm, in February 2025 for $600 million, and the acquisition included transfer of Ambry’s database. The transferred database is alleged to have contained the genetic information of hundreds of thousands of Ambry customers. Plaintiffs assert the database was transferred without obtaining prior written consent from individuals. The complaints allege this conduct violated the Illinois Genetic Information Privacy Act. The lawsuits are brought as class actions seeking relief on behalf of affected individuals.

The complaints further allege Tempus used the collected genetic information to train its AI models and that Tempus shared genetic data with pharmaceutical companies for profit. The lawsuits seek damages and an injunction to prevent Tempus from further sharing the genetic information. The update includes a disclaimer noting the generality of the information and advising specific legal advice. The piece appears on a Robinson+Cole Data Privacy + Security Insider feed hosted on JD Supra and notes attorney advertising. No final judicial determination is reported in the extracted text; the assertions in the complaints are described as alleged.